Royalty Payments; Reports. (a) Upon execution of this Agreement, and upon renewal of this Agreement as set forth in Paragraph 3 above, Licensee shall pay to University an annual licensing fee of one hundred dollars ($100). Within thirty (30) days of the end of the Initial Term and, if applicable, each respective Renewal Period, Licensee shall provide University with a written report of number of Licensed Articles sold and pay to University any additional fees due based on Licensee’s annual gross sales as set out in Appendix C and incorporated herein. In the event that Licensee’s annual gross sales for the Initial Term or Renewal Period, as applicable, exceed $5,000, Licensee shall pay University a royalty of sixteen percent (16%) of the Gross Sales in excess of $5,000.
Royalty Payments; Reports. Within [***] ([***]) days after the end of each calendar quarter for which royalties are due by Ono to Merus, Ono shall pay Merus all such amounts payable by it under Section 6.4 by wire transfer on a country by country basis. Each such payment shall be accompanied with a report, providing in reasonable detail an accounting of all Net Sales made during such calendar quarter and the calculation of any royalties due under Section 6.4.
Royalty Payments; Reports. Tanabe shall, (i) for a period equaling the longer of ten (10) years from the date of the initial sale of each Product for each indication in the Territory or the expiration of the last Signal Patent, Joint Patent or Tanabe Patent (including in each case patents deemed to exist as a result of a Use or Structure Contribution by Tanabe, Signal or both Parties) which claims the use or sale of such Product in the country of sales, pay to Signal a royalty in U.S. dollars equal to the percentages ("Royalty Rates") set forth in Exhibit D and (ii) for so long as sales of any Product gives rise to an obligation by Signal to pay patent royalties to a Third Party, reimburse Signal for any and all such Third-Party patent royalties ("Third-Party Royalties"), subject to Section 5.4(e) below, due by Signal pursuant to its license ("Reimbursements"). Thereafter, [***] Tanabe shall remain liable for all royalties payable by its Affiliates or sublicensees.
Royalty Payments; Reports. Beginning with the calendar quarter in which the first commercial sale of the first Royalty Product in the Territory has taken place, royalty payments and reports of the sale of the applicable product(s) for each calendar quarter will be calculated and delivered to Ilypsa under this Restated Agreement within forty-five (45) days of the end of such calendar quarter. Each royalty payment shall be accompanied by a report of Net Sales setting forth (a) Net Sales on a Royalty Product-by-Royalty Product and country-by-country basis during the applicable calendar quarter; and (b) a calculation of the royalty payment due hereunder for such calendar quarter for each Royalty Product. [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
Royalty Payments; Reports. Payments of royalties to SEQUENOM under Article ------------------------ 5.2 based upon Net Revenues will be made on a monthly basis and within thirty (30) days of the close of each calendar month. With each monthly payment, SPECIALTY shall provide SEQUENOM with a written report setting forth sufficient information to verify Net Revenues received by SPECIALTY.
Royalty Payments; Reports. (a) Within [*] days after the end of each [*] of Licensee's Fiscal Year, Licensee shall:
Royalty Payments; Reports. Payments of royalties to SEQUENOM under Article 5.2 based upon Net Revenues will be made on a monthly basis and within thirty (30) days of the close of each calendar month. With each monthly payment, SPECIALTY shall provide SEQUENOM with a written report setting forth sufficient information to verify Net Revenues received by SPECIALTY.
Royalty Payments; Reports. Royalties under Section 8.4 shall be calculated and reported for each Calendar Quarter during the Royalty Term and shall be paid within thirty (30) Business Day after the end of the applicable Calendar Quarter, commencing with the Calendar Quarter in which the First Commercial Sale of a Product occurs. Each payment of royalties shall be accompanied by a report of Net Sales of the Products by Advaccine, its Affiliates and their respective Sublicensees in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including: (a) the amount of gross sales and Net Sales of the Products in the Advaccine Territory on a Product-by-Product and Region-by-Region basis, (b) an itemized calculation showing the deductions from gross sales (by major category as set forth in the definition of Net Sales) to determine Net Sales, and (c) a calculation of the amount of royalties due to Inovio in U.S. Dollars, including the application of any exchange rate used.
Royalty Payments; Reports. Royalties under Section 8.4 shall be calculated and reported for each calendar quarter during the Royalty Term and shall be paid within sixty (60) days after the end of the applicable calendar quarter, commencing with the calendar quarter in which the First Commercial Sale of a Licensed Product occurs. Each payment of royalties shall be accompanied by a report of Net Sales of Licensed Products by SAMR, its Affiliates and their respective sublicensees in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including: (a) the amount of gross sales and Net Sales of Licensed Products in the Applicable Territory on a Licensed Product-by-Licensed Product basis, (b) an itemized calculation showing the deductions from gross sales (by major category as set forth in the definition of Net Sales) to determine Net Sales and (c) a calculation of the amount of royalties due to Aridis in U.S. Dollars, including the application of any exchange rate used.
Royalty Payments; Reports. Royalties under Section 8.6 shall be calculated and reported for each Calendar Quarter during the Royalty Term and shall be paid within [***]after the end of the applicable Calendar Quarter, commencing with the Calendar Quarter in which the First Commercial Sale of a Licensed Product occurs. Each payment of royalties shall be accompanied by a report of Net Sales of Licensed Products by 3D Medicines, its Affiliates and their respective Sublicensees in sufficient detail to permit confirmation of the accuracy of the royalty payment made, including: (a) the amount of gross sales and Net Sales of Licensed Products in the 3D Medicines Territory on a Licensed Product-by-Licensed Product and Region-by-Region basis, (b) an itemized calculation showing the deductions from gross sales (by major category as set forth in the definition of Net Sales) to determine Net Sales, and (c) a calculation of the amount of royalties due to Aravive in U.S. Dollars, including the application of any exchange rate used.
